CA-ARRCUS
Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, announces the enhancement of its ACE-AI platform to address the growing demand for unified networking fabric for distributed AI workloads.
As AI workloads become increasingly distributed, driven by economic considerations and application requirements, Arrcus ACE-AI is a platform designed to seamlessly network them across various locations and deliver applications at the edge, with high speed and lossless connectivity. The emerging federated learning model for AI allows multiple entities to collaboratively train a model with decentralized data. Training models may be executed in hyperscale environments while inference models may be executed at the edge for various use cases. Arrcus recognizes the need for a unified networking fabric that interconnects these workloads, regardless of where they may reside. Modern data center applications demand high throughput (400-800Gbps) and ultra-low latency (< 10μs per hop), and Arrcus ACE-AI meets these demands while minimizing CPU overhead.
"The future of AI lies in its ubiquity, and Arrcus has built the industry’s most flexible and intelligent fabric that connects and orchestrates distributed AI workloads,” said Shekar Ayyar, Chairman and CEO of Arrcus. “With the enhanced ACE-AI platform, we are giving enterprises and service providers the power to unlock the full potential of AI, across clouds, data centers, and the edge."
Emerging artificial intelligence, high-performance computing, and storage workloads pose new challenges for large-scale datacenter networking. Arrcus addresses these challenges by supporting new features that build a lossless Ethernet fabric, including RoCEv2, PFC, ECN, ETS, AR, Dynamic Load Balancing, and Global Load Balancing.
One of the significant challenges in achieving high-performance networking for AI workloads is the limitation of traditional TCP/IP stacks at such speeds due to their high CPU overhead. Arrcus addresses this challenge by incorporating RDMA (Remote Direct Memory Access) technology, which offloads transport communication tasks from the CPU to hardware, providing direct memory access for applications without involving the CPU. The second version of RDMA over Converged Ethernet (RoCE-v2) further enhances the protocol with UDP/IP headers with routing.
In addition to these feature enhancements, Arrcus is also pleased to announce support for new industry-leading platforms from Broadcom that are state-of-the-art 800G switching platforms – Tomahawk5, Jericho3, Ramon3 – in partnership with device manufacturers like Ufispace and Edgecore.
"Broadcom is very excited to collaborate with Arrcus to deliver industry-leading switching solutions that are optimized to meet the performance demands of next-generation AI workloads. Together, Arrcus and Broadcom are enabling customers to build high-performance, scalable, and intelligent data center networks,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.
Key features that make Arrcus the industry’s leading networking platform for AI:
- High-Performance Networking for AI: Support for industry-leading hardware with Broadcom switches like Tomahawk5 and Jericho3-AI, RoCEv2, SmartNICs from NVIDIA and Intel, and enabling ultra-low latency (< 10μs per hop) and high throughput (400-800Gbps) required by modern AI applications.
- Multi-Cloud Cost Optimization: Enhanced FlexMCN with Egress Cost Control (ECC) technology empowers users to analyze, allocate, and dynamically route traffic across clouds for optimal cost efficiency, reducing egress charges by up to 15%.
- Automated 5G Network Slicing for AI: Integration of SRv6 Mobile User Plane (MUP) and Flex Algo enables automated delivery of AI applications with 5G network slicing, streamlining service deployment and resource allocation.
- End-to-End Network Visibility with ArcIQ: New ArcIQ capabilities extend real-time network insights to user equipment, providing actionable data for proactive incident management.
With these latest capabilities and dedication to innovation, Arrcus is enabling organizations to break through the limitations of traditional networking and embrace the full potential of distributed AI. The enhanced ACE-AI platform signifies a pivotal step in building the intelligent fabric for the AI-powered future.
Additional Resources
- Arrcus Unveils Groundbreaking ACE-AI Networking Solution
- Arrcus Delivers Next Generation of High-Performance, Zero-Trust Networking for Datacenters Enabled by NVIDIA BlueField
About Arrcus
Arrcus was founded to enhance business efficiency through superior network connectivity. The Arrcus Connected Edge (ACE) platform offers best-in-class networking with the most flexible consumption model at the lowest total cost of ownership. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners and top-tier VCs. The company is headquartered in San Jose, California, with offices in Bangalore, India, and Tokyo, Japan. For more information, go to www.arrcus.com or follow @arrcusinc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226461853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
